Barbara Eichhorst, MD of the University of Cologne, Cologne, Germany, provides a brief overview of previous and current trial results of combination drugs for high-risk groups with chronic lymphocytic leukemia (CLL). At last years American Society of Hematology (ASH) meeting, first data on frontline therapy with the BCL2 inhibitor venetoclax, had been presented showing high complete responses (CR). At this years ASH, data has been submitted on the safety run-in phase of the CLL14 study (NCT02242942), evaluating obinutuzumab and venetoclax with reports on the response rates, including minimal residual disease (MRD) rates. Recorded at the 2016 International Workshop of the German CLL Study Group (GCLLSG) in Cologne, Germany.
Obinutuzumab and venetoclax for high-risk CLL: upcoming CLL14 trial
